Literature DB >> 15180634

The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer.

C Vallbo1, W Wang, J-E Damber.   

Abstract

OBJECTIVE: To evaluate the immunohistochemical expression of thrombospondin (TSP), a potent inhibitor of angiogenesis, in human benign prostatic hyperplasia (BPH) and prostate cancer.
MATERIALS AND METHODS: The expression of TSP-1, TSP-2 and CD36 receptor was assessed in 73 tissue specimens using immunohistochemistry; specimens were from 32 patients with BPH, seven with prostatic intraepithelial neoplasia (PIN) and 34 with cancer.
RESULTS: Immunohistochemistry showed that all 39 patients with BPH and PIN had TSP-1-positive glands. In contrast, none of the 34 patients with cancer had positive TSP-1 staining in the cancer tissue. All 73 patients were positive for TSP receptor CD36 and negative for TSP-2.
CONCLUSIONS: TSP is expressed in BPH, down-regulated in PIN and absent in prostate cancer tissue. This may indicate that TSP is important in prostate cancer progression. Further studies are needed to understand the significance of these findings for the malignant transformation of the prostate gland.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15180634     DOI: 10.1111/j.1464-410x.2004.04818.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

1.  ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors.

Authors:  Heléne Gustavsson; Tajana Tesan; Karin Jennbacken; Kouji Kuno; Jan-Erik Damber; Karin Welén
Journal:  BMC Cancer       Date:  2010-06-14       Impact factor: 4.430

2.  Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression.

Authors:  Gustavo Ayala; Matteo Morello; Anna Frolov; Sungyong You; Rile Li; Fabiana Rosati; Gianluca Bartolucci; Giovanna Danza; Rosalyn M Adam; Timothy C Thompson; Michael P Lisanti; Michael R Freeman; Dolores Di Vizio
Journal:  J Pathol       Date:  2013-07-08       Impact factor: 7.996

3.  Beta1 integrin cytoplasmic variants differentially regulate expression of the antiangiogenic extracellular matrix protein thrombospondin 1.

Authors:  Hira Lal Goel; Loredana Moro; Joanne E Murphy-Ullrich; Chung-Cheng Hsieh; Chin-Lee Wu; Zhong Jiang; Lucia R Languino
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

Review 4.  Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies.

Authors:  Jeff S Isenberg; Gema Martin-Manso; Justin B Maxhimer; David D Roberts
Journal:  Nat Rev Cancer       Date:  2009-02-05       Impact factor: 60.716

Review 5.  Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.

Authors:  Yasuyoshi Miyata; Hideki Sakai
Journal:  Int J Mol Sci       Date:  2013-06-07       Impact factor: 5.923

6.  Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer.

Authors:  Annalisa Macagno; Alcibiade Athanasiou; Anja Wittig; Ramy Huber; Stephan Weber; Thomas Keller; Martin Rhiel; Bruno Golding; Ralph Schiess
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

Review 7.  Should EMT of Cancer Cells Be Understood as Epithelial-Myeloid Transition?

Authors:  Henning M Schramm
Journal:  J Cancer       Date:  2014-01-15       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.